Breast Cancer Research and Treatment

Papers
(The H4-Index of Breast Cancer Research and Treatment is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Intraoperative assessment of axillary sentinel lymph nodes by telepathology124
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia105
Area deprivation index and breast cancer outcomes among patients in Western New York69
Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer63
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study62
Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis54
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer52
Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis50
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial43
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study40
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy35
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study35
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience34
Integrating SENOMAC and AMAROS: a call for de-escalation33
Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients33
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis32
Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study31
Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study31
Prognostic and predictive impact of NOTCH1 in early breast cancer31
Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study28
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients28
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy28
Chronic inflammatory diseases and survival among breast cancer patients in the U.S. military health system27
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis27
SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast26
Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study26
0.16476488113403